Archive · 24 Dec 2025
FDA Approves Novo Nordisk's Wegovy Pill
Novo Nordisk, a big medicine company from Denmark, got permission from the US FDA to sell a new weight loss pill called Wegovy.
This news made their stock price go up by more than 7%.
The pill is supposed to help people lose weight and keep it off, and it's also good for their heart.
Novo Nordisk plans to start selling the pill in the US early next year.
Their stock has been doing well over the last five years, but it went down a lot in the last year.
The company is also asking other places, like Europe, to approve the pill too.
The pill is taken once a day on an empty stomach and has shown good results in helping people lose weight.
Some people might feel sick to their stomach, but it's not very common.
Novo Nordisk's stock price jumped over 7% after FDA approval of the Wegovy pill on 22 December 2025.
The Wegovy pill is a once-daily medication aimed at reducing excess body weight and cardiovascular risks.
Novo Nordisk plans to launch the Wegovy pill in the US by early January 2026.
The company's stock has seen a 52% increase over five years but a 47.68% decrease over the past year.
Novo Nordisk has submitted the Wegovy pill for approval to the European Medicines Agency (EMA) and other regulatory authorities.
- Who
- Novo Nordisk, a Denmark-based pharmaceutical company
- What
- Received FDA approval for the Wegovy pill, a weight loss drug
- When
- 22 December 2025
- Where
- United States
- Why
- To provide a convenient, once-daily pill for weight loss and cardiovascular risk reduction
- Company
- Novo Nordisk
- Stock Price Increase
- 7.18%
- Current Stock Price (DKK)
- 325.30
- Previous Close (DKK)
- 303.50
- Market Capitalization (DKK)
- 1.35 trillion
- Market Capitalization (USD)
- $211.7 billion
- 52-Week High (DKK)
- 675.20
- 52-Week Low (DKK)
- 266.90
- 5-Year Returns
- 52%
- 1-Year Returns
- -47.68%
- 1-Month Returns
- 13.50%
- 5-Day Returns
- 6%
- ADR Stock Price (USD)
- $51.29
- Previous ADR Close (USD)
- $48.10
- Approval Date
- 22 December 2025
- Expected Launch Date (US)
- Early January 2026
- Regulatory Submissions
- EMA and other authorities (H2 2025)
- Active Ingredient
- Semaglutide
- Dosage Forms
- 1.5mg, 4mg, 9mg, 25mg
- Initial Dose Cost
- $149
- Weight Loss (Highest Dose)
- 16.6%
- Clinical Trial Duration
- 64 weeks
- Side Effects
- Nausea, vomiting, gastrointestinal issues
Sources
Novo Nordisk stock jumps over 7% after weight loss drug Wegovy pill gets US FDA nod — Details here
No injections needed! FDA approves THIS ‘once-daily’ oral weight loss pill – All you need to know
A pill a day to keep obesity away?
